

3. Gurney JK, Florio AA, Znaor A, et al. International Trends in the Incidence of Testicular Cancer: Lessons from 35 Years and 41 Countries. *Eur Urol.* 2019;76(5):615-623.
4. Nicol D, Berney DM, Boormans JL, et al. EAU Guidelines on Testicular Cancer, presented at the EAU Annual Congress Paris 2024.
5. Huang J, Chan SC, Tin MS, et al. Worldwide Distribution, Risk Factors, and Temporal Trends of Testicular Cancer Incidence and Mortality: A Global Analysis. *Eur Urol Oncol.* 2022;5(5):566-576.
6. Oosterhuis JW, Looijenga LHJ. Testicular germ-cell tumours in a broader perspective. *Nat Rev Cancer.* 2005;5(3):210-222.
7. ÚZIS. Cancer incidence 2019–2021 in the Czech Republic.
8. Patel HD, Gupta M, Cheaib JG, et al. Testis-sparing surgery and scrotal violation for testicular masses suspicious for malignancy: A systematic review and meta-analysis. *Urol Oncol.* 2020;38(5):344-353.
9. Skoogh J, Steineck G, Cavallin-Ståhl E, et al. Feelings of loss and uneasiness or shame after removal of a testicle by orchidectomy: a population-based long-term follow-up of testicular cancer survivors. *Int J Androl.* 2011;34(2):183-192.
10. Gilligan T, Lin DW, Aggarwal R, et al. Testicular Cancer, Version 1.2024, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Cancer Netw.* 2024;17(12):1529-1554.
11. Dieckmann K-P, Kulejewski M, Pichlmeier U, et al. Diagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two-site biopsies are more sensitive than a single random biopsy. *Eur Urol.* 2007;51(1):175-183;discussion 183-185.
12. Høe-Hansen CE, Rajpert-De Meyts E, Daugaard G, et al. Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review. *Ann Oncol Off J Eur Soc Med Oncol.* 2005;16(6):863-868.
13. Dieckmann K-P, Wilken S, Loy V, et al. Treatment of testicular intraepithelial neoplasia (intratubular germ cell neoplasia unspecified) with local radiotherapy or with platinum-based chemotherapy: a survey of the German Testicular Cancer Study Group. *Ann Oncol Off J Eur Soc Med Oncol.* 2013;24(5):1332-1337.
14. Mortensen MS, Gundgaard MG, Daugaard G. Treatment options for carcinoma in situ testis. *Int J Androl.* 2011;34(4 Pt 2):e32-36.
15. Warde P, Specht L, Horwich A, et al. Prognostic Factors for Relapse in Stage I Seminoma Managed by Surveillance: A Pooled Analysis. *J Clin Oncol.* 2002;20(22):4448-4452.
16. Mortensen MS, Lauritsen J, Gundgaard MG, et al. A Nationwide Cohort Study of Stage I Seminoma Patients Followed on a Surveillance Program. *Eur Urol.* 2014;66(6):1172-1178.
17. Chovanec M, Cheng L. Advances in diagnosis and treatment of testicular cancer. *BMJ.* 2022; e070499.
18. Coleman JM, Coleman RE, Turner AR, et al. The management and clinical course of testicular seminoma: 15 years' experience at a single institution. *Clin Oncol (R Coll Radiol).* 1998;10(4):237-241.
19. Santoni R, Barbera F, Bertoni F, et al. Stage I seminoma of the testis: a bi-institutional retrospective analysis of patients treated with radiation therapy only. *BJU Int.* 2003;92(1):47-52; discussion 52.
20. Jones WG, Fossa SD, Mead GM, et al. Randomized Trial of 30 Versus 20 Gy in the Adjuvant Treatment of Stage I Testicular Seminoma: A Report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). *J Clin Oncol.* 2005;23(6):1200-1208.
21. Travis LB, Ng AK, Allan JM, et al. Second Malignant Neoplasms and Cardiovascular Disease Following Radiotherapy. *JNCI J Natl Cancer Inst.* 2012;104(5):357-370.
22. Hellesnes R, Myklebust TÅ, Fosså SD, et al. Testicular Cancer in the Cisplatin Era: Causes of Death and Mortality Rates in a Population-Based Cohort. *J Clin Oncol.* 2021;39(32):3561-3573.
23. Oliver RTD, Mason MD, Mead GM, et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. *Lancet (London, England).* 366(9482):293-300.
24. Albers P, Siener R, Kliesch S, et al. Risk Factors for Relapse in Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors: Results of the German Testicular Cancer Study Group Trial. *J Clin Oncol.* 2003;21(8):1505-1512.
25. Sweeney CJ, Hermans BP, Heilman DK, et al. Results and Outcome of Retroperitoneal Lymph Node Dissection for Clinical Stage I Embryonal Carcinoma – Predominant Testis Cancer. *J Clin Oncol.* 2000;18(2):358-358.
26. Blok JM, Pluim I, Daugaard G, et al. Lymphovascular invasion and presence of embryonal carcinoma as risk factors for occult metastatic disease in clinical stage I nonseminomatous germ cell tumour: a systematic review and meta-analysis. *BJU Int.* 2020;125(3):355-368.
27. Tandstad T, Ståhl O, Häkansson U, et al. One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group. *Ann Oncol.* 2014;25(11):2167-2172.
28. Albers P, Siener R, Kregge S, et al. Randomized Phase III Trial Comparing Retroperitoneal Lymph Node Dissection With One Course of Bleomycin and Etoposide Plus Cisplatin Chemotherapy in the Adjuvant Treatment of Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors: AUO Trial AH 01/94. *J Clin Oncol.* 2008;26(18):2966-2972.
29. Beck SDW, Bey AL, Bihrlé R, et al. Ejaculatory Status and Fertility Rates After Primary Retroperitoneal Lymph Node Dissection. *J Urol.* 2010;184(5):2078-2080.
30. Classen J, Schmidberger H, Meisner C, et al. Radiotherapy for Stages IIA/B Testicular Seminoma: Final Report of a Prospective Multicenter Clinical Trial. *J Clin Oncol.* 2003;21(6):1101-1106.
31. Domont J, Massard C, Patrikidou A, et al. A risk-adapted strategy of radiotherapy or cisplatin-based chemotherapy in stage II seminoma. *Urol Oncol Semin Orig Investig.* 2013;31(5):697-705.
32. Heinzelbecker J, Schmidt S, Lackner J, et al. Therapy of clinical stage IIA and IIB seminoma: a systematic review. *World J Urol.* 2022;40(12):2829-2841.
33. Giannatempo P, Greco T, Mariani L, et al. Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes. *Ann Oncol Off J Eur Soc Med Oncol.* 2015;26(4):657-668.
34. Daneshmand S, Cary C, Masterson T, et al. Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy. *J Clin Oncol.* 2023;41(16):3009-3018.
35. Hiester A, Che Y, Lusch A, et al. Phase 2 Single-arm Trial of Primary Retroperitoneal Lymph Node Dissection in Patients with Seminomatous Testicular Germ Cell Tumors with Clinical Stage IIA/B (PRIMETEST). *Eur Urol.* 2023;84(1):25-31.
36. Loriot Y, Texier M, Culine S, et al. The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. *Eur Urol.* 2022;82(2):172-179.
37. Nicolai N, Nazzani S, Tesone A, et al. Retroperitoneal lymph-node dissection (RPLND) as upfront management in stage II germ-cell tumours: Evaluation of safety and efficacy. *Tumori.* 2023;109(4):379-386.
38. Bokemeyer C, Kollmannsberger C, Stenning S, et al. Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials. *Br J Cancer.* 2004;91(4):683-687.
39. King J, Dropcho S, Beeler S, et al. A phase II trial evaluating the efficacy of cabozantinib in the treatment of patients with refractory germ-cell tumors (GCT). *J Clin Oncol.* 2022;40(6 suppl):TPS428–TPS428.
40. Necchi A, Anichini A, Raggi D, et al. Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure. *Clin Genitourin Cancer.* 2016;14(4):261-264.e4.
41. Albany C, Fazal Z, Singh R, et al. A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer. *Cancer Med.* 2021;10(1):156-163.
42. Tandstad T, Stahl O, Dahl O, et al. The ABC-study: A randomized phase III study comparing one course of adjuvant bleomycin, etoposide, and cisplatin (BEP) and one course of carboplatin AUC7 in clinical stage I seminomatous testicular cancer. *J Clin Oncol.* 2017;35(15 suppl):TPS4593–TPS4593.
43. Swiss Group for Clinical Cancer Research. Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma. *NCT03937843.*
44. Feliciani G, Mellini L, Carnevale A, et al. The potential role of MR based radiomic biomarkers in the characterization of focal testicular lesions. *Sci Rep.* 2021;11(1):3456.
45. Lobo J, Zogchel LMJ van, Nuru MG, et al. Combining Hypermethylated RASSF1A Detection Using ddPCR with miR-371a-3p Testing: An Improved Panel of Liquid Biopsy Biomarkers for Testicular Germ Cell Tumor Patients. *Cancers (Basel).* 2021;13(20):5228.

Urologie pro praxi
www.urologiepropraxi.cz

